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BACKGROUND AND PURPOSE: The physiopathologic bases underlying the signal intensity changes and
reduced diffusibility observed in prion diseases (TSEs) are still poorly understood. We evaluated the
interest of MRS combined with DWI both as a diagnostic tool and a way to understand the mechanism
underlying signal intensity and ADC changes in this setting.
MATERIALS AND METHODS: We designed a prospective study of multimodal MR imaging in patients
with suspected TSEs. Forty-five patients with a suspicion of TSE and 11 age-matched healthy
volunteers were included. The MR imaging protocol included T1, FLAIR, and DWI sequences. MRS
was performed on the cerebellum, pulvinar, right lenticular nucleus, and frontal cortex. MR images
were assessed visually, and ADC values were calculated.
RESULTS: Among the 45 suspected cases, 31 fulfilled the criteria for probable or definite TSEs (19
sCJDs, 3 iCJDs, 2 vCJDs, and 7 genetic TSEs); and 14 were classified as AltDs. High signals in the
cortex and/or basal ganglia were observed in 26/31 patients with TSEs on FLAIR and 29/31 patients on
DWI. In the basal ganglia, high DWI signals corresponded to a decreased ADC. Metabolic alterations,
increased mIns, and decreased NAA were observed in all patients with TSEs. ADC values and
metabolic changes were not correlated; this finding suggests that neuronal stress (vacuolization),
neuronal loss, and astrogliosis do not alone explain the decrease of ADC.
CONCLUSIONS: MRS combined with other MR imaging is of interest in the diagnosis of TSE and
provides useful information for understanding physiopathologic processes underlying prion diseases.
ABBREVIATIONS: ADC  apparent diffusion coefficient; AltD  alternative diagnosis; Avg  average;
C (or c)  control; Cho  choline; CJD  Creutzfeldt-Jakob disease; Cr  creatine; DWI  diffusion-
weighted imaging; EEG  electroencephalograph; FFI  fatal familial insomnia; FLAIR  fluid-attenu-
ated inversion recovery; GABA  gamma-aminobutyric acid; gCJD  genetic CJD; Glx  glutamine-
glutamate-GABA; GSS  Gerstmann Strausser Sheinker syndrome; iCJD  iatrogenic CJD; mIns 
myo-inositol; MM methionine homozygosity (PRNP: genotype at codon 129); MRS MR spectros-
copy; MRI  MR imaging; MV  methionine-valine heterozygosity (PRNP: genotype at codon 129);
NA  data not available; NAA  N-acetylaspartate; NS  not significant or nonspecific slow waves; P
(or p)  patient; PRNP  genotype at codon 129; PrP  prion protein or persistent plexus gene; S 
sum of metabolites; sCJD  sporadic CJD; TSE  human transmissible spongiform encephalopathy;
vCJD  variant CJD; VV  valine homozygosity (PRNP: genotype at codon 129)
MR imaging has become a tool of choice in the diagnosis ofseveral forms of prion diseases (TSEs). The presence of ar-
eas of increased signal intensity, usually associated with a de-
creased ADC, are frequently observed on the cortex, thalamus,
and/or basal ganglia of patients with sCJD, vCJD, or iCJD. How-
ever, the exact physiopathologic processes underlying these
changes are still subject to debate. They have been variously at-
tributed to the PrP deposits, the morphologic changes of neu-
rons, or gliosis.1-3 Correlation of these signal-intensity changes
with pathologic data is further impaired by their modification
during the time course of the disease.4-6 MRS can, on the other
hand, be performed simultaneously with conventional imaging
and can give information on the ongoing pathologic processes:
Neuronal lossor stresswill lead toadecrease inNAA,while gliosis
will induce an increase in the resonance ofmIns.Hence, to deter-
mine the diagnostic value of MRS in TSEs and to better under-
stand thephysiopathologic processes underlying the signal inten-
sity/ADC changes, we prospectively studied 45 patients clinically
suspected of having prion diseases with amultimodalMR imag-
ing protocol, including MRS and conventional and diffusion
imaging.
Materials and Methods
This prospective studywas approved by the committee on ethics of La
Timone Hospital. Patients (or their representatives) and controls
gave written informed consent to participate in the study.
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Selection and Classification of Patients
Patients were referred to the neurology departments of La Pitie´ Sal-
peˆtrie`re (Paris) and La Timone hospital (Marseille) for suspicion of
TSEs (sporadic, genetic, iatrogenic, or variant). This diagnosis was
reassessed by 2 neurologists who were experts in prion diseases
(J.-P.B. and S.H.). Patients then underwent a multimodal MR imag-
ing, which was part of an extensive evaluation, including 14.3.3 pro-
tein detection in theCSF, EEG, and genotyping of thePrP gene. Tonsil
biopsies were performed when vCJD was suspected. Postmortem ex-
amination was performed in 9 subjects. The eventual diagnosis was
based on the World Health Organization clinical diagnostic criteria
for prion diseases.7 The pathologic findings in the patient with FFI
were published in a previous article.8
MR Imaging Protocol
MR imaging examinations were performed on 1.5T magnets at La
Pitie´ Salpeˆtrie`re, Paris (Signa HDx; GE Healthcare, Milwaukee, Wis-
consin) and at La Timone Hospital, Marseille (Vision; Siemens, Er-
langen, Germany). Patients were given a light sedation with hy-
droxyzine dichlorhydrate, 100 mg, when required by their clinical
status. Pulse saturometry was monitored during the procedure. Total
time inside the magnet was approximately 1 hour. The MR imaging
protocol included the following:
1) A sagittal T1-weighted sequence.
2) One axial T1-weighted sequence (TR  644 ms, TE  15 ms,
3-mm thickness, interleaved).
3) An axial FLAIR sequence (TR 8000ms, TI 2200ms, TE 110
ms, 5-mm thickness, interleaved).
4) DWI (single-shot echo-planar imaging sequence; b 0, 500, 1000
s/mm2 applied in the x, y, and z directions sequentially; 19 sec-
tions; 5-mm thickness; matrix  128  128; FOV  256  256
mm2). ADC maps were reconstructed by using this sequence as
previously described.9
5) Four stimulated echo acquisition mode single-voxel spectroscopy
acquisitions (TR 1500ms, TE 20ms, TM 30ms) on regions
known to be frequently involved in prion diseases: the cerebellar
vermis (voxel size, 20 20 15mm), the pulvinar (voxel location
as previously described10), the right lenticular nucleus (voxel size,
35 15 15mm), and the bifrontal cortex (voxel size, 40 20
15 mm). The locations of the voxels are shown on Fig 1.
Processing of MR Images and Spectra
MR images were analyzed with 2 methods:
1) MR imaging examinations were interpreted by 2 expert neurora-
diologists (D.G. and D.D.). Signal intensity on FLAIR and DWIs
was evaluated side by side in cortical regions (frontal, temporoin-
sular, and parieto-occipital) and 3 areas of the basal ganglia (cau-
date, putamen, and thalamus). Signal intensity was ranked from 1
to 4 as follows: 1, normal; 2, dubious area of increased signal in-
tensity; 3, obvious area of increased signal intensity; and 4, area of
markedly increased signal intensity. Differences between observ-
ers were settled by consensus.
2) ADC values were calculated by using the software provided by the
manufacturers in the following locations: head of the caudate nu-
clei, putamen, thalamus, and pulvinar. ADC regions were drawn
on the DWI image, on the section on which each nucleus had the
greatest extension. The voxel included the whole structure present
on this section minus the pixels closest to the ventricles, to avoid
partial volume effect. Because of partial volume effects, we did not
calculate the ADC in the cerebellum and frontal cortex.
Quantification of MR Spectra
TheMRS data were analyzed by using a dedicated software described
elsewhere.11 Resonances were assigned according to those described
in the literature.12,13 Spectra were processed as previously de-
scribed.14,15 Briefly, we manually corrected the baselines and inte-
grated the resonances of the following metabolites: NAA, Cr, Cho,
mIns, and Glx. The value of each metabolite was then divided by the
sum (S NAA Cr ChomIns Glx) of all metabolite values
(semiquantitative evaluation). This semiquantitative analysis, the
sum of metabolites, was preferred to the calculation of individual
metabolite ratios (eg, NAA/Cr or Cho/Cr), which are dependent on
both numerator and denominator variations. For instance, a de-
creased NAA/Cr ratio could be attributed to both a reduction in NAA
(resulting from neuronal stress) or an increase in Cr (resulting from a
glial activation or proliferation).16-18 Ratios of the sum ofmetabolites
“smoothen” these variations and enable a better evaluation of the
variations of the metabolite in the numerator. However, we did eval-
uate the mIns/NAA ratio. Because NAA is a neuronal marker and
mIns is a glial marker, this ratio simultaneously evaluates neuronal
stress/death and gliosis, which are 2 of the main histologic landmarks
of prion diseases. The presence of detectable free lipids and lactate was
also assessed.
Statistical Analysis
Statistical analysis was performed by using the JMP software (SAS
Institute, Cary, North Carolina). Differences among patients, volun-
teers, and AltDs were determined by a Kruskal-Wallis analysis fol-
lowed by a Scheffe´ test with a Bonferroni correction for multiple
comparisons. The statistical analysis was also performed on the sub-
group of patients with sCJD, who were compared with controls by
using an unpaired Student t test. Due to the small numbers and het-
erogeneity of the other subtypes of CJD and AltDs, no further statis-
tical analysis could be performed on these patients and their meta-
bolic anomalies were only described.
Fig 1. Location of the MRS voxels on axial FLAIR (A and C) and sagittal T1-weighted (B) sequences: lenticular nucleus (1), pulvinar (2), cerebellar vermis (3), and frontal cortex (4).
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Results
Forty-five patients were prospectively studied. The diagno-
sis of prion diseases was eventually confirmed in 31 subjects
and included 1 FFI, 1 GSS, 2 vCJD, 3 iCJD related to growth
hormone treatment of CJD, 5 gCJD, and 19 sCJD. Themean
time between first symptoms and the MR imaging exami-
nation was 7 months. The median duration of disease in
sCJD was 7 months. Genotype at codon 129 of the PRNP
gene was determined in 29/31 subjects. The patients’ main
clinical and paraclinical characteristics are shown in Table 1.
The diagnoses for the other 14 patients were the following:
2 Alzheimer diseases, 1 vascular dementia, 1 Hashimoto en-
cephalitis, 1 depression, 1 metabolic, 1 epileptic encephalopa-
thy, 1 atypical Parkinson disease, 1 paraneoplastic syndrome,
and 5 dementias of unknown etiology.
Conventional Imaging
High signals in the cortex and/or basal ganglia were observed
in 26/31 patients with TSEs on FLAIR sequence. The 5 patients
with normal findings on the FLAIR sequence were the ones
with FFI and the GSS, 1/19 sCJD and 1/3 iCJD, and 1 codon
200 mutation of the 5 cases of gCJD.
On the DWI sequence, 29/31 patients had abnormalities:
26/31 on the cortical areas and 25/31 on the basal ganglia. The
3 patients with normal FLAIR findings and lesions on theDWI
Fig 2. Typical images in cases of sCJD (A), vCJD (B), and gCJD (C). FLAIR, DWI, and ADC
map, respectively, are shown. Areas of increased signal intensity, which involve the cortex
and the striatum are more extensive and more clearly visible on diffusion images. On the
basal ganglia, these changes are associated with a decreased ADC. There is widespread
involvement of the cortex in the patient with sCJD. gCJD and vCJD both present with
lesions of the thalamus and lenticular nuclei. However, in the variant case, as opposed to
the genetic one, the areas of high signal intensity are more pronounced in the pulvinar than
in the striatum as has been previously described in this phenotype.
Table 1: Main clinical and paraclinical data of patients
No. Form Age (yr) PRNP EEGa 14.3.3b Durationc MRI Delayedd
1 FFIe 54 MM D178N-129 mol/L NS – 6 5
2 gCJDe 69 MM E200K   4 6
3 gCJDe 58 MM E200K  NA 6 3
4 gCJDe 49 MV D178N-129V – – 10 4
5 gCJDe 70 MV V203I NS  11 10
6 gCJDe 67 MM E200K NA NA 5 3
7 iCJD 18 MV NA – 16 6
8 iCJD 34 MV   23 8
9 iCJDe 25 MM – – 12 8
10 GSSe 47 MV P102 L – – 54 27
11 vCJD 43 MM  – 15 12
12 vCJD 52 MM NS – 8 7
13 sCJD 66 NA NA NA NA 3
14 sCJDe 54 MV   10 6
15 sCJDe 62 MM   19 7
16 sCJDe 66 VV   4 2
17 sCJDe 51 MM   4 2
18 sCJD 56 MV –  13 8
19 sCJD 74 MM NA NA 3 2
20 sCJD 52 MM   3 2
21 sCJDe 81 MM   4 4
22 sCJD 53 MV NS  21 1
23 sCJD 55 MV  – 60 23
24 sCJD 80 MV  – 9 8
25 sCJD 77 MV  – 24 10
26 sCJD 40 NA NA NA 10 9
27 sCJD 72 MM   3 2
28 sCJDe 64 MM   4 1
29 sCJD 55 NA –  26 20
30 sCJD 84 NA NA NA 5 3
31 sCJD 80 NA NS – 2 1
Note:— – indicates not present.
a Indicates periodic sharp wave complexes.
b Detection of 14.3.3 protein in the CSF.
c Duration of the disease in months.
d Time in months between first symptoms and MR imaging examination.
e The diagnosis was confirmed by postmortem examination and/or mutation was present in the PRNP. PRNP : genotype at codon 129 (MM, VV, MV) and mutation when present.
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sequence were the patient with gCJD, who presented clear
abnormalities on both cortical areas and basal ganglia; the one
with sCJD, who had widespread involvement of the cortex;
and the one with iatrogenic CJD, who had clear involvement
of the striatum.
Neither patients with an AltD nor the control subjects had
areas of increased signal intensity or reduced diffusibility in
the cortex or basal ganglia.
Typical images are shown on Fig 2. The frequency of in-
volvement of the major brain structures is summarized on
Table 2.
ADC Values
ADC values were significantly reduced in the head of the cau-
date nuclei, thalamus, pulvinar, and lenticular nuclei in pa-
tients with prion disease compared with controls (P 102 in
all cases). This difference was also present when the analysis
was restricted to subjects with sCJD.
In patients with AltDs, ADC values were not significantly
different from those of controls.
MRS
A summary ofMRS results is given inOn-line Table 1. Typical
spectra are shown in Fig 3. MRS could be performed in all
patients and controls. Some spectra had to be excluded be-
cause of poor quality in 1 control (lenticular voxel) and 2
patients with CJD (a pulvinar acquisition in a patient with
sCJD and a lenticular acquisition in the patient with FFI). No
difference was observed in the metabolic ratios between the
controls in the 2 MR imaging centers.
The NAA/S, the mIns/S, andmIns/NAA ratios showed dif-
ferences in the global (Kruskal-Wallis) analysis. No othermet-
abolic ratio was significantly different between groups. The
NAA/S ratio was lower and the mIns/S and mIns/NAA ratios
were higher in patients with prion disease comparedwith con-
trols inmost studied voxels (On-line Table 1). ThemIns/NAA
ratio was the only one to be significantly different in all 4
voxels (Fig 4).
In the lenticular and pulvinar nuclei, where both MRS was
performed and ADC values could be calculated, no metabolic
ratio was significantly correlated to ADC values (Fig 5), re-
gardless of the presence of areas of increased signal intensity in
FLAIR or DWI.
No parameter on DWI or MRS was correlated to the sur-
vival of the patients.
Discussion
While the value of MR imaging for the diagnosis of most sub-
types of prion diseases has beenwell established in several large
retrospective studies, the pathologic bases of the observed sig-
nal-intensity changes on diffusion and T2/FLAIR images are
still imperfectly understood. Correlating signal intensity or
ADC changes with the findings at autopsy is of crucial impor-
tance but should be complemented by in vivo studies because
it is known that the pattern of lesions on MR imaging can
change during the course of the disease,4,6,19,20 and because the
interval between MR imaging and death is often long. MRS is
a noninvasive method to study brain metabolism, which can
be performed during the same examination as diffusion imag-
ing and can thus allow the synchronous evaluation of diffusion
lesions and cellular changes.
The MRS results in our study are in accordance with the
classic pathologic findings in prion diseases. The metabolic
alterations are a decrease in NAA/S, which corresponds to
neuronal stress and death, and an increase in mIns/S, which is
a marker of gliosis. To our knowledge, this study is the first
prospective evaluation of MRS in human prion diseases. Our
findings are similar to those reported in previously published
articles of human and animalmodels of prion diseases.4,10,21-27
We did not observe any correlation between ADC values and
any metabolic ratio. This does not support neuronal stress
such as vacuolization (spongiform changes) as themain factor
that could explain a reduced diffusibility of water.28 Because
gliosis increases ADC,3 we can speculate a role for PrP deposits
in the decrease of ADC. The normalization of the ADC values
observed in some patients later in the course of the disease
could be explained at least in part by the subsequent develop-
ment of gliosis.8 This hypothesis could be verified with fol-
low-up examinations, which could show an increase in mIns.
However, while they were initially intended in our study, they
could not be performed due to the rapidly worsening clinical
condition of most patients. A specific postmortem study of
radiopathologic correlations with extensive quantification of
tissue alterations, including spongiform change, astrogliosis,
microglial activation, and neuronal loss together with an as-
sessment of abnormal protein accumulation, will help to bet-
ter understand the pathologic supports of each neuroradio-
logic perturbation. The distinct prion-related lesions may
influence differently, and sometimes with opposite effects,
each MR imaging component.
The high frequency of metabolic alterations on MRS in
patients with prion diseases can be explained by the targeting
of MRS to the regions most commonly affected by these dis-
eases. However, metabolic alterations were not present in all 4
locations in every patient. This is in accordance with the het-
erogeneous distribution of the pathologic changes in these dis-
eases.29 In addition, variations in NAA andmIns were also not
systematically associated and could be found separately. These
results are in agreement with the pathologic pattern of prion
diseases, which diversely associates neuronal impairment and
gliosis and varies among brain regions.
Table 2: Number of patients presenting with areas of significant
(>3 on the visual scale) increased signal/decreased ADC in the
different brain structuresa
N  31 FLAIR DWI
Frontal 17 25
Parietal 15 18
Temporal 14 18
Occipital 11 13
Insula 11 15
Cortex, all 19 26
Lenticular 18 23
Caudate 16 23
Thalamus 6 11
Basal ganglia, all 20 25
Brain stem 1 2
Global 26 29
a The most frequently involved cerebral lobes are the frontal, the temporal, and the parietal.
In the deep brain structures, the lenticular and the caudate nuclei are affected in a similar
number of patients
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The coherence of these results with the pathologic data is
reinforced by the findings in some subtypes: In the 2 cases of
vCJD, the most severely affected areas were the pulvinars,30
with a marked decrease in NAA/S and increase in mIns/S ra-
tios, with vCJD being characterized by the occurrence of se-
vere neuronal loss with intense gliosis in this region. In addi-
tion, the 3 patients with iCJD exhibited stronger decreased
NAA/S in the cerebellum compared with the population with
sCJD. This is in agreement with the early and predominant
cerebellar symptoms and the neuropathologic patterns that
are regularly observed in this form.31
We observed a higher sensitivity of FLAIR (84%) than was
previously reported by Tschampa et al32 in a large retrospec-
tive study (47%) of patients from different institutions. This
can probably be explained by a homogeneous acquisition pro-
tocol on similar MR imaging magnets in our study.
The sensitivity (94%) of diffusion imaging was higher than
previously observed in retrospective studies32,33 and similar
(92.3%) to the only prospective study that evaluated DWI in
prion diseases so far.34 This sequence is thus clearly the most
sensitive among conventional MR imaging acquisitions for
the diagnosis of prion diseases. The 2 cases with negative find-
ings were genetic forms (1 FFI and 1 GSS). All cases of sCJD,
gCJD, and iCJD had abnormalities on the DWI sequence. No
patient with an AltD had areas of decreased ADC, confirming
the high specificity of DWI for the diagnosis of prion diseases
in the clinical setting of dementia of rapid onset.
One of 19 patients with sCJD had no lesions on the FLAIR
sequence. The cortex was involved in 16/19 patients and the
basal ganglia, in 13/19. All patients had areas of increased sig-
nal intensity on DWI, involving the cortex (19/19) and the
basal ganglia (15/19). The distribution of lesions among the
cortex and basal ganglia was similar to the one reported re-
cently by Meissner et al.35 Results of the analysis of MRS and
Fig 3. Typical spectra recorded in a patient with sCJD (left column) and in a healthy volunteer (right column) in the vermis, pulvinar, right lenticular nucleus, and frontal gray matter.
Metabolic anomalies are observed on the bifrontal voxel (decreased NAA and increased mIns), on the lenticular voxel (decreased NAA), and on the bipulvinar voxel (decreased NAA and
increased mIns). Note that to get an accurate idea of NAA and mIns variations, one should compare their resonances with “stable” metabolites (eg, Cr).
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ADC data performed on this subgroup of patients were com-
parable to those of the total group of patients with prion dis-
eases (On-line Table 1).
Among the 17 patients with sCJD forwhich the genotype of
PRNP at codon 129 was available, 9 had the MM; 7, the MV;
and 1, the VV phenotype. Median duration of the disease was
4months for theMMphenotype and 11.5months for patients
with MV and VV phenotypes. On FLAIR imaging, lesions of
the basal ganglia were more frequent in patients with the MV
or VV (7/8) phenotypes than in subjects with the MM (4/9)
phenotype.
MR imaging findings in gCJD were heterogeneous. The
patient with mutation D178N-129V had extensive areas of
increased signal intensity on the cortex, on both FLAIR and
DWI, with onlyminimal involvement of the basal ganglia (hy-
persignal of the left caudate). One patient with mutation 200
had no abnormalities on the FLAIR sequence but showed ar-
eas of hypersignal on the DWI sequences in the left striatum
and frontal and insular cortices. The 2 other patients with
mutation 200 had marked hypersignals in the striatum on
both FLAIR and DWI imaging. Involvement of the cortex was
also present on DWI. These results (frequency of involvement
Fig 4. ADC values in the lenticular (A) and caudate (B) nuclei and mIns/NAA ratios on the vermis (C), pulvinar (D), right lenticular nucleus (E), and frontal gray matter (F) in patients with
prion disease (p), controls (c), and those with AltD. ADC is decreased and mIns/NAA is increased in patients with prion disease compared with both controls and AltDs. Neither ADC values
nor the mIns/NAA ratios can discriminate between the 2 latter groups.
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of the basal ganglia and cortical lesions detected on DWI) are
comparable with those previously described in a population of
subjects with mutation 200.36 The patient with mutation
V203I had diffuse lesions on both the cortex and basal ganglia.
ADC values were diminished in the basal ganglia of all pa-
tients. Spectroscopic findings in the 5 genetic cases were sim-
ilar to those of sporadic cases.
Among patients with iCJD, FLAIR imaging findings were
normal in 1 patient; showed lesions restricted to the striatum
in 1; and evidenced widespread involvement of the striatum,
thalamus, periaqueductal gray matter, and cortex in another.
On DWI, all patients showedmarked areas of increased signal
intensity in the striatum,whichwere associatedwith decreased
ADC values. The 3 cases of iCJD had in common a markedly
reduced NAA/S in the cerebellar vermis. MRS results were
otherwise heterogeneous.
We observed the classic imaging pattern of vCJD, with hy-
persignals of the basal ganglia in both FLAIR and DWI se-
quences, predominating in the pulvinar (pulvinar sign). No
lesions were seen on the cortex. The 2 patients with vCJD had
similar spectroscopic findings, in accordance with previously
published reports ofMRS in this disease by the authors (about
a previous patient) and others.10,21,26 A pronounced decrease
in NAA/S and an increase in mIns/S were present in the pulv-
inar. Themetabolic abnormalities in the lenticular nuclei were
limited to an increase in mIns, and the metabolic profiles of
the vermis and the frontal cortex were both normal.
The patient with FFI had normal findings on FLAIR and
DWI. Most interesting, as opposed to all other cases of prion
diseases, ADC values were increased in the thalamus com-
pared with those in healthy volunteers. MRS showed a de-
crease in NAA/S on the pulvinar, associated with an increased
mIns/S. The metabolic profiles of the frontal cortex and of the
vermis were normal, and the lenticular nucleus was not
interpretable.
The patient with GSS had normal findings on FLAIR and
DWI, except a moderate cerebellar atrophy. ADC values were
within the normal range in all the locations studied. MRS
showed diffuse changes overall similar to those of patients
with sCJD. The most striking abnormality was a pronounced
decrease in NAA/S in the lenticular nucleus.
Conclusions
Metabolic changes were detected in all patients with sporadic,
inherited, or infectious prion diseases in at least 1 of the stud-
ied voxels, even in areas that looked normal on conventional
imaging. In addition, we confirm, in this prospective study,
that DWI has the highest sensitivity (94%) among the conven-
tional MR imaging sequences. No metabolic ratio was corre-
lated to ADC values, indicating that these 2 imaging modali-
ties explore different pathologic processes. It should now be of
great interest to confirm the specificity of DWI and MRS by a
study on a large non-CJD population with dementia and to
explore further the neuropathologic bases of MR imaging al-
terations in humans and in experimental in vivo models of
prion diseases.
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